<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: Vertex Gears up for Big Liver Disease Conference</title>
	<atom:link href="http://www.xconomy.com/boston/2008/10/29/vertex-gears-up-for-big-liver-disease-conference/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.xconomy.com/boston/2008/10/29/vertex-gears-up-for-big-liver-disease-conference/</link>
	<description>Business + Technology in the Exponential Economy</description>
	<lastBuildDate>Sat, 11 Feb 2012 03:54:18 +0000</lastBuildDate>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0.4</generator>
	<item>
		<title>By: The Man</title>
		<link>http://www.xconomy.com/boston/2008/10/29/vertex-gears-up-for-big-liver-disease-conference/comment-page-1/#comment-36676</link>
		<dc:creator>The Man</dc:creator>
		<pubDate>Thu, 30 Oct 2008 20:41:42 +0000</pubDate>
		<guid isPermaLink="false">http://www.xconomy.com/?p=5882#comment-36676</guid>
		<description>It&#039;s 2-3 years behind TVR and still in the early stages of development. Considering the vast expanse of the Phase II graveyard, it still has a long way to go.</description>
		<content:encoded><![CDATA[<p>It’s 2-3 years behind TVR and still in the early stages of development. Considering the vast expanse of the Phase II graveyard, it still has a long way to go.</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Jim</title>
		<link>http://www.xconomy.com/boston/2008/10/29/vertex-gears-up-for-big-liver-disease-conference/comment-page-1/#comment-36671</link>
		<dc:creator>Jim</dc:creator>
		<pubDate>Thu, 30 Oct 2008 20:25:18 +0000</pubDate>
		<guid isPermaLink="false">http://www.xconomy.com/?p=5882#comment-36671</guid>
		<description>I am somewhat surprised that TMC435350 from Medivir/J&amp;J is not mentioned as being a potential competitor for Telaprevir. Once daily should be a great advantage and so far all available data by far exceeds that of Telaprevir.</description>
		<content:encoded><![CDATA[<p>I am somewhat surprised that TMC435350 from Medivir/J&amp;J is not mentioned as being a potential competitor for Telaprevir. Once daily should be a great advantage and so far all available data by far exceeds that of Telaprevir.</p>
]]></content:encoded>
	</item>
</channel>
</rss>

